Blurbs

Needham Thinks Aerie Pharma’s Stock is Going to Recover

In a report released today, Serge Belanger from Needham maintained a Buy rating on Aerie Pharma (AERIResearch Report), with a price target of $22.00. The company’s shares closed last Thursday at $7.46, close to its 52-week low of $6.67.

According to TipRanks.com, Belanger is a 1-star analyst with an average return of -0.3% and a 37.3% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and Collegium Pharmaceutical.

Currently, the analyst consensus on Aerie Pharma is a Moderate Buy with an average price target of $21.00.

See the top stocks recommended by analysts >>

The company has a one-year high of $21.30 and a one-year low of $6.67. Currently, Aerie Pharma has an average volume of 1.14M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.

Read More on AERI:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos